CoolSeal® Generator

    Delivers precisely the power needed with the gold-standard efficacy of advanced bipolar radiofrequency (RF) technology.

    CoolSeal Generator

      Overview

      Documents

      Training

      The Proprietary Vessel Sealing Algorithm

      CoolSeal's innovative vessel sealing algorithm delivers the precise power needed to achieve optimal tissue temperature for vessel sealing and fusion.

      Simple to Use

      Entire CoolSeal portfolio is powered by the simple to use, plug and play generator.

      Fast seals

      Produce consistently strong, secure seals in less than 2 seconds on average.1

      Efficient energy

      Optimized tissue effect, where seal strength is maintained, but seal times, thermal spread, and total energy delivery are reduced.

      CoolSeal Generator

      CoolSeal Generator

      • Gold-standard efficacy of advanced bipolar RF vessel sealing technology 
      • Delivers precisely the power needed 
      • Powers the entire CoolSeal portfolio of devices

      Need Support?

      All Other Requests

      CoolSeal Portfolio

      Vizient Awarded Supplier

      Vizient Award

      The CoolSeal® advanced energy portfolio and JustRight® 5mm stapler were awarded the Innovative Technology designation from Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company. Vizient awarded the contract after hospital experts who served on one of its provider-led councils recommended CoolSeal and JustRight. 

      These provider-led councils evaluate products submitted through Vizient’s Innovative Technology Program. They recommend contracts for technologies that have the potential to enhance clinical care, patient safety and healthcare worker safety, or to improve business operations of healthcare organizations.

      View the Hologic press release.

        1. NAR-EN-17455 Rev 1 CoolSeal Trinity LigaSure Maryland Seal Time Comparison Report 2. NAR-VE-17353 Rev 2 3. NAR-VE-17357 Rev 2 4. NAR-EN-17449 Rev 1 CoolSeal Trinity Cooling Time Marketing Claims Test Report 5. 16457 Rev 1 CoolSeal™ Reveal Seal Plate Cooldown Comparison Marketing Report Average cooling time following a single activation

        Safety Data Sheets

        Package Inserts

        Panther Fusion® Respiratory Assays

        Placeholder image

          Overview

          Package Inserts

          Resources

          Syndromic Respiratory Testing.

          Patient-Specific Results.

          The Panther Fusion Respiratory assays are the premier set of assays on the Panther Fusion® system. You can provide truly personalized syndromic respiratory testing with qualitative detection and differentiation of the most common respiratory viruses from a single patient sample. Each Panther Fusion Respiratory assay can be processed independently or simultaneously with other Panther Fusion® and Aptima® assays.

          The Panther Fusion® SARS-CoV-2/Flu A/B/RSV, Panther Fusion® Flu A/B/RSV, Panther Fusion® Paraflu, Panther Fusion® AdV/hMPV/RV and Panther Fusion® Bordetella assays comprise the CE-IVD respiratory testing menu on the fully automated Panther Fusion system. Each is a multiplex, real-time PCR in vitro diagnostic test. These assays can be run on nasopharyngeal (NP) swab specimens obtained from individuals exhibiting signs and symptoms of a respiratory tract infection.1-5 Additionally, the Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization for the detection of SARS-CoV-2 from nasopharyngeal, nasal, mid-turbinate and oropharyngeal swab specimens, nasopharyngeal wash/aspirate or nasal wash, and lower respiratory tract specimens.6

          Personalized Respiratory Testing

          The Panther Fusion assays provide the flexibility to run patient-specific targets, allowing for personalized patient testing and better cost control in your lab.

          •  
          • The Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay§ - Qualitative detection and differentiation of SARS-CoV-2, influenza A virus, influenza B virus and respiratory syncytial virus.1
          • The Panther Fusion® Flu A/B/RSV assay - Qualitative detection and differentiation of influenza A virus, influenza B virus and respiratory syncytial virus.2
          • The Panther Fusion® AdV/hMPV/RV assay - Qualitative detection and differentiation of adenovirus, human metapneumovirus and rhinovirus.3
          •  
          •  
          • The Panther Fusion® Paraflu assay - Qualitative detection and differentiation of parainfluenza 1 virus, parainfluenza 2 virus, parainfluenza 3 virus and parainfluenza 4 virus.4
          • The Panther Fusion® Bordetella assay - Qualitative detection and differentiation of Bordetella pertussis and Bordetella parapertussis.5
          • The Hologic® SARS-CoV-2 assays* - Qualitative detection of SARS-CoV-2 virus.6-8
          •  

          Flex Your Ability

          With the Panther Fusion Respiratory assays, a single patient specimen can be tested for SARS-CoV-2 as well as other common respiratory viruses which present with overlapping symptoms, boosting efficiency and increasing clinical insight.

          Additionally, when you leverage the power of Panther Fusion, your lab can:

          • Run more efficiently with full automation from sample-to-result.
             
          • Receive easy-to-interpret results.
             
          • Personalize syndromic respiratory testing by processing multiple assays from a single specimen.
             
          • Control costs by running only the required assays and reduce expense of unnecessary tests.
             
          • Eliminate the need for reagent preparation with Panther Fusion’s ready-to-use format.
             
          • Reduce waste with 60 day on-board reagent stability.
             
          • Consolidate menu onto a single, fully automated platform with the ability to run both Aptima and Panther Fusion assays alongside each other at the same time.

          Safety Data Sheets

          Need Support?

          All Other Requests

           

          * The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2 and Aptima SARS-CoV-2/Flu assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima SARS-CoV-2/Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A virus, Flu B virus, and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
           
          †The Panther Fusion Bordetella Assay is TGA approved and CE marked, it is not Health Canada approved.
          ‡The Panther Fusion SARS-CoV-2 Assay is Health Canada and TGA approved, it is not CE marked.
          §The Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay is CE marked, it is not Health Canada or TGA approved. In development and not for sale in the U.S.
          References: 1. Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. Package insert AW-25328. Hologic, Inc.; 2022. 2. Panther Fusion A/B/RSV assay. Package insert AW-16162 Hologic, Inc.; 2018. 3. Panther Fusion AdV/hMPV/RV assay. Package insert AW-16164. Hologic, Inc.; 2019. 4. Panther Fusion Paraflu assay. Package insert AW-16163. Hologic, Inc.; 2018. 5. Panther Fusion Bordetella assay. Package insert AW-18637. Hologic, Inc.; 2018. 6. Panther Fusion SARS-CoV-2 assay. Package insert AW-21388. Hologic, Inc.; 2021. 7. Aptima SARS-CoV-2 assay. US package insert AW-21492-001. Hologic, Inc.; 2021. 8. Panther Fusion SARS-CoV-2/Flu assay. US package insert AW-22364. Hologic, Inc; 2021.